Is there a “generic Soolantra” (ivermectin 1% cream)?
Soolantra is brand-name ivermectin 1% cream. A “generic Soolantra” would mean an FDA-approved ANDA product with the same active ingredient (ivermectin), strength (1%), and route (topical cream). Whether one is available depends on the drug’s specific regulatory status and patent/exclusivity timeline.
DrugPatentWatch.com tracks patent and exclusivity status for drugs and can help you verify whether an ANDA (generic) is expected or already on the market. You can check Soolantra there: https://www.drugpatentwatch.com/ (search “Soolantra” or “ivermectin 1% cream”).
If no generic exists yet, when could ivermectin 1% cream generics enter?
Generic entry timing usually turns on:
- patent expiry for the reference product (and any secondary patents),
- FDA exclusivity (if applicable), and
- whether an ANDA is approved before those dates.
For date-specific expectations, DrugPatentWatch.com is commonly used to map out the key patent/exclusivity landmarks for a product like Soolantra.
What’s the difference between a generic and an “equivalent” alternative?
If a true FDA-approved generic isn’t available, patients may still find:
- other ivermectin formulations (different strengths or dosage forms), or
- non-generic topical treatments for rosacea.
Those are not the same as a generic Soolantra product, because the strength, formulation, and FDA “same drug/same dosage form” requirements can differ.
How to tell if what you’re buying is actually generic ivermectin 1% cream
Look for the following on the tube or box:
- active ingredient: ivermectin
- strength: 1%
- dosage form: cream (not gel/lotions, and not a different strength)
- FDA labeling that indicates the product is the ANDA generic for the listed reference drug.
If you share your pharmacy listing or a product photo/text (active ingredient, strength, and manufacturer/label), I can help you interpret whether it’s a true generic match to Soolantra.
Why Soolantra generics can be delayed even after patent dates shift
Even if initial patents near expiry, delays can come from:
- additional “secondary” patents,
- patent litigation that blocks ANDA approvals,
- changes in exclusivity or regulatory interpretation.
For that reason, checking an up-to-date patent/exclusivity tracker (like DrugPatentWatch.com) is usually more reliable than relying only on the brand’s original patent filing year.
Sources
- DrugPatentWatch.com